Patents Assigned to ACADEMY OF MILITARY MEDICAL SCIENCES
-
Patent number: 10314794Abstract: The invention relates to a drug sustained-release composition, particularly a sustained-release composition comprising metoprolol and preparation method thereof. The invention also relates to a combination product comprising a sustained-release composition comprising metoprolol and a pharmaceutical composition comprising hydrochlorothiazide. The sustained-release composition comprising metoprolol according to the invention eliminates the phenomena of delayed release of such sustained-release compositions in the prior art, has a better drug release curve, and also have the advantages such as simple formula, easy operation, stable quality, strong controllability, and good reproducibility, and therefore have good application prospects.Type: GrantFiled: June 23, 2015Date of Patent: June 11, 2019Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Chunsheng Gao, Yuli Wang, Meiyan Yang, Li Shan, Jingjing Dai, Yong Qian, Yan Qiu
-
Patent number: 10301279Abstract: The present invention provides a compound of a general formula I, a stereomeride, pharmaceutically acceptable salt or a solvate thereof, a preparation method thereof, and usages in preparing medicines for preventing and/or treating diseases or symptoms caused by drug-resistant tumors or drug-resistant bacteria and in preparing medicines for preventing and/or treating diseases or symptoms related to tumors, neurodegenerative diseases, allogeneic transplantation rejection, and infection. Preferably, the diseases or symptoms related to tumors, neurodegenerative diseases, allogeneic transplantation rejection, and infection are diseases or symptoms caused by a heat shock protein 70 (Hsp70). The compound in the present invention is used for overcoming a difficult problem of drug resistance of tumors, improves the effect of tumor treatment, and provides a new medical strategy for clinical tumor treatment.Type: GrantFiled: October 26, 2017Date of Patent: May 28, 2019Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Wu Zhong, Song Li, Yanqun Zeng, Junhai Xiao, Xinbo Zhou, Zhibing Zheng, Xingzhou Li, Xiaokui Wang
-
Publication number: 20190077821Abstract: Disclosed in the present invention is a compound of Formula (I), a geometric or optical isomer, a pharmaceutically acceptable salt, a solvate or a polymorph thereof. Also disclosed in the present invention is a composition comprising the compound of Formula (I), the geometric or optical isomer, the pharmaceutically acceptable salt, the solvate or the polymorph thereof. Also disclosed in the present invention is a use of the compound of Formula (I), the geometric or optical isomer, the pharmaceutically acceptable salt, the solvate or the polymorph thereof in the treatment of a disease or disorder such as a hypoglutamatergic condition, a neurodegenerative disease or respiratory depression, particularly in the treatment of a disease or disorder associated with AMPA receptor.Type: ApplicationFiled: April 11, 2017Publication date: March 14, 2019Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song LI, Xinbo ZHOU, Dian XIAO, Wu ZHONG, Junhai XIAO, Zhibing ZHENG, Xingzhou LI, Yunde XIE, Xiaokui WANG
-
Publication number: 20190062290Abstract: The present invention relates to a 2,3-epoxy succinyl derivative, a preparation method and a use thereof, in particular, the present invention relates to a compound represented by Formula (1), a racemate or an optical isomer thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof. The compound according to the present invention has good inhibitory activity and/or selectivity against cathepsin, especially Cathepsin B, can be used in the treatment of multiple diseases associated with cathepsin, for example, osteoporosis, rheumatoid arthritis and osteoarthritis that are associated with Cathepsin K, Ebola virus infection, a degenerative disease and an autoimmune disease that are associated with Cathepsin L, S, especially Cathepsin B-related tumor diseases, such as gastric cancer, cervical cancer, lung cancer, breast cancer, prostate cancer, bladder cancer, colon cancer, neuroglioma, and melanoma.Type: ApplicationFiled: March 2, 2017Publication date: February 28, 2019Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song LI, Junhai XIAO, Xiaoye ZHANG, Hongliang WANG, Wu ZHONG, Zhibing ZHENG, Yunde XIE, Xingzhou LI, Xinbo ZHOU, Xiaokui WANG
-
Patent number: 10196411Abstract: The invention relates to tizoxanide phosphate or alkane sulfonate compounds represented by Formula I, and pharmaceutically acceptable salts thereof, isomers thereof, hydrates thereof or solvates thereof, and pharmaceutical applications of the compounds.Type: GrantFiled: December 11, 2015Date of Patent: February 5, 2019Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song Li, Xingzhou Li, Wu Zhong, Zhibing Zheng, Junhai Xiao, Xinbo Zhou, Yunde Xie, Xiaokui Wang, Lili Wang, Wei Chen, Fei Xie
-
Patent number: 10196346Abstract: The present invention pertains to the field of pharmaceutical chemicals, and relates to a substituted acethydrazide derivative, preparation method and use thereof; preferably, relates to a compound of Formula I or a pharmaceutically acceptable salt thereof. The compound of the present invention or a pharmaceutically acceptable salt thereof can effectively inhibit proline hydroxylase, stabilize HIF-?, particularly HIF-1?, and has potency in the manufacture of a medicament for treatment and/or prophylaxis and/or adjuvant therapy of anemia, acute ischemic reperfusion injury.Type: GrantFiled: November 20, 2017Date of Patent: February 5, 2019Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song Li, Junhai Xiao, Lili Wang, Long Long, Wei Li, Haoming Luo, Feifei Li, Wu Zhong, Zhibing Zheng, Yunde Xie, Xingzhou Li, Xinbo Zhou, Xiaokui Wang, Ruiyuan Cao
-
Patent number: 10172932Abstract: Provided are an Ebola virus envelope glycoprotein (that is GP protein) codon optimized nucleotide sequence, a human replication deficient recombinant adenovirus capable of expressing the nucleotide sequence, and applications in preparing a vaccine for preventing Ebola virus diseases. The nucleotide sequence takes a replication deficient 5 type adenovirus that is lack of E1 and E3 in a combined mode as a vector. HEK293 cells that integrate adenovirus E1 genes serve as a packaging cell line, and carried protective antigenic genes are codon optimized Zaire type Ebola virus Makona strain envelope glycoprotein genes. After the envelope glycoprotein genes are optimized by codon, the expression level in transfection cells is obviously improved.Type: GrantFiled: October 24, 2016Date of Patent: January 8, 2019Assignee: Institute of Biotechnology, Academy of Military Medical Science, PLAInventors: Wei Chen, Shipo Wu, Lihua Hou, Xiaohong Song, Jinlong Zhang, Ling Fu
-
Publication number: 20180370928Abstract: The present invention relates to a compound represented by Formula I, a racemate or optical isomer thereof, or a pharmaceutically acceptable salt, a solvate or a hydrate thereof, a pharmaceutical composition comprising the compound, and a use thereof in the manufacture of a medicament for preventing and/or treating a disease or disorder associated with a viral infection.Type: ApplicationFiled: November 24, 2016Publication date: December 27, 2018Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song LI, Junhai XIAO, Libao XU, Ruiyuan CAO, Fangyuan CAO, Hongliang WANG, Wu ZHONG, Zhibing ZHENG, Yunde XIE, Xingzhou LI, Xinbo ZHOU, Xiaokui WANG
-
Patent number: 10160767Abstract: The present invention pertains to the field of pharmaceutical chemicals, and relates to a rapamycin derivative of Formula I, and a preparation method, pharmaceutical composition and use thereof. The compounds of the present invention overcome the defects of rapamycin in terms of water solubility and metabolic properties, and some of the compounds have an in vitro anti-tumor activity superior to rapamycin, have less toxicity to normal cells than rapamycin, and have very good druggability.Type: GrantFiled: June 3, 2015Date of Patent: December 25, 2018Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Wu Zhong, Song Li, Shuang Cao, Ruiyuan Cao, Junhai Xiao, Xinbo Zhou, Xingzhou Li
-
Patent number: 10131643Abstract: The invention relates to a tizoxanide carbamate compound of Formula I and a pharmaceutically acceptable salt, a hydrate or a solvate thereof, and their pharmaceutical use.Type: GrantFiled: July 4, 2014Date of Patent: November 20, 2018Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song Li, Xingzhou Li, Wu Zhong, Zhibing Zheng, Junhai Xiao, Xinbo Zhou, Yunde Xie, Xiaokui Wang, Lili Wang, Wei Chen, Fei Xie
-
Publication number: 20180282368Abstract: The present invention discloses a method for separating and purifying ?2-macroglobulin from Cohn Fraction IV precipitation, in which Cohn Fraction IV precipitation is treated by ammonium sulfate precipitation, zinc ion affinity chromatography, gel filtration, and ultrafiltration and concentration sequentially and thereby ?2-macroglobulin is obtained finally. With the method provided in the present invention, purified ?2-macroglobulin plasma protein that has a clinical application value is obtained, the Cohn Fraction IV precipitation is changed from a discarded material into a valuable material, and plasma is utilized comprehensively. In addition, the method is easy and simple to use, easy to scale up, and suitable for separation and purification of ?2-macroglobulin at a large scale.Type: ApplicationFiled: September 14, 2016Publication date: October 4, 2018Applicant: ACADEMY OF MILITARY MEDICAL SCIENCESInventors: Jingang ZHANG, Chaoji HUANGFU, Xiong ZHAO, Maomin LV, Yuyuan MA, Junting JIA
-
Publication number: 20180264100Abstract: Provided are an Ebola virus envelope glycoprotein (that is GP protein) codon optimized nucleotide sequence, a human replication deficient recombinant adenovirus capable of expressing the nucleotide sequence, and applications in preparing a vaccine for preventing Ebola virus diseases. The nucleotide sequence takes a replication deficient 5 type adenovirus that is lack of E1 and E3 in a combined mode as a vector. HEK293 cells that integrate adenovirus E1 genes serve as a packaging cell line, and carried protective antigenic genes are codon optimized Zaire type Ebola virus Makona strain envelope glycoprotein genes. After the envelope glycoprotein genes are optimized by codon, the expression level in transfection cells is obviously improved.Type: ApplicationFiled: October 24, 2016Publication date: September 20, 2018Applicant: Institute of Biotechnology, Academy of Military Medical Science, PLAInventors: Wei Chen, Shipo Wu, Lihua Hou, Xiaohong Song, Jinlong Zhang, Ling Fu
-
Publication number: 20180258145Abstract: The invention provided a method for preparing a bacterial polysaccharide-modified recombinant fusion protein and use of the bacterial polysaccharide-modified recombinant fusion protein. The method comprises: co-expressing a recombinant fusion protein and the Neisseria meningitidis O-oligosaccharyltransferase PglL in an O-antigen ligase gene-defective bacterium, and linking a polysaccharides endogenous or exogenous for the bacterium to the recombinant fusion protein by the O-oligosaccharyltransferase PglL, to obtain the bacterial polysaccharide-modified recombinant fusion protein. The protein can be used for preparing antibodies against bacterial polysaccharides and vaccines.Type: ApplicationFiled: September 1, 2015Publication date: September 13, 2018Applicant: Institute of Biotechnology, Academy of Military Medical Sciences, ChinaInventors: Jun WU, Chao PAN, Peng SUN, Hengliang WANG, Bo LIU, Zhehui PENG, Li ZHU, Shaohong CHANG, Xin GONG, Erling FENG, Bin WANG, Ming ZENG
-
Patent number: 10071994Abstract: The invention relates to a homoserine lactone derivative of Formula I, preparation method and use thereof.Type: GrantFiled: May 25, 2015Date of Patent: September 11, 2018Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song Li, Junhai Xiao, Qi Sun, Wu Zhong, Lili Wang, Zhibing Zheng, Yunde Xie, Xingzhou Li, Xinbo Zhou, Xiaokui Wang, Ruiyuan Cao
-
Patent number: 10035771Abstract: The present invention discloses a class of mercaptonicotinic acid compound and preparation method and use thereof; the general structural formula of the compound is as shown in Formula I. Experiment demonstrates that the mercaptonicotinic acid compound could inhibit activity of botulinum toxin endopeptidase and tetanus toxin endopeptidase in vitro, which has a significant protective effect on botulinum toxin poisoning in mice, and can be used for preparing medicine intended to prevent and/or treat botulism, as well as to prevent botulinum toxin exposure and tetanus.Type: GrantFiled: May 19, 2014Date of Patent: July 31, 2018Assignee: INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY, ACADEMY OF MILITARY MEDICAL SCIENCES, PR CHINAInventors: Hui Wang, Wannian Zhng, Zhenyuan Miao, Tao Li, Xiong Liu, Yuelin Wu, Sen Luo, Chunquan Sheng, Xiaoxue Lu, Jianzhong Yao
-
Patent number: 10023565Abstract: The present invention relates to a compound of formula (I), a stereomeride, pharmaceutically acceptable salt, a solvate or an N-oxide thereof, a medicine composition comprising the compound, a method for preparing the compound, and a usage of the compound in treating diseases related to Hsp70. The diseases are preferably selected from tumors, neurodegenerative diseases, and allogeneic transplantation rejection and infection.Type: GrantFiled: December 19, 2014Date of Patent: July 17, 2018Assignee: INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINAInventors: Wu Zhong, Song Li, Yanqun Zeng, Junhai Xiao, Xinbo Zhou, Zhibing Zheng, Xingzhou Li, Xiaokui Wang, Lili Wang
-
Publication number: 20180185376Abstract: The invention belongs to the technical field of medicines. In particular, the invention relates to a thiazideamide derivative compound or a pharmaceutically acceptable salt or solvate thereof, a pharmaceutical composition comprising the compound or a pharmaceutically acceptable salt or solvate thereof, a method for preparing the compound or a pharmaceutically acceptable salt or solvate thereof, and a use of the compound or a pharmaceutically acceptable salt or solvate thereof. For example, the compound or a pharmaceutically acceptable salt or solvate thereof according to the invention can be used to prevent and/or treat a neurodegenerative disease or a neuropathic disease caused by a physical trauma or a related disease.Type: ApplicationFiled: June 28, 2016Publication date: July 5, 2018Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song LI, Junhai XIAO, Boqun LYU, Hongqiang WANG, Wu ZHONG, Lili WANG, Zhibing ZHENG, Yunde XIE, Xinbo ZHOU, Xingzhou LI, Xiaokui WANG
-
Publication number: 20180179193Abstract: The invention relates to a homoserine lactone derivative of Formula I, preparation method and use thereof. The compound has an effect of regulatory of bacterial quorum sensing, and is useful for preventing and/or treating a disease caused by infection of a bacterium.Type: ApplicationFiled: May 25, 2015Publication date: June 28, 2018Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song LI, Junhai XIAO, Qi SUN, Wu ZHONG, Lili WANG, Zhibing ZHENG, Yunde XIE, Xingzhou Li, Xinbo ZHOU, Xiaokui WANG, Ruiyuan CAO
-
Patent number: 9999540Abstract: A dropper of eye drops comprises an eye drops storage for storing eye drops, which has an opening at the top and an eye drop outlet at the bottom; an elastic seal assembly installed inside the eye drop storage and forming a space for storing the eye drops together with the eye drop outlet; a pressing device installed at the top of the eye drop storage and configured to press the elastic seal assembly so as to compress the space for storing the eye drops, such that the eye drops are dropped out of the eye drop outlet. The dropper of eye drops eye drops by means of pressing the pressing device, and thus can be operated simply and safely, time- and energy-saving, and avoid waste. In addition, the dropper of eye drops has a simple design in structure and is convenient for use.Type: GrantFiled: May 24, 2013Date of Patent: June 19, 2018Assignee: Affiliated Hospital, China Academy of Military Medical SciencesInventors: Yanfeng Yang, Sugang Liu, Zisu Peng, Xinghuo Qiu
-
Publication number: 20180134653Abstract: The present invention pertains to the field of pharmaceutical chemicals, and relates to a substituted acethydrazide derivative, preparation method and use thereof; preferably, relates to a compound of Formula I or a pharmaceutically acceptable salt thereof. The compound of the present invention or a pharmaceutically acceptable salt thereof can effectively inhibit proline hydroxylase, stabilize HIF-?, particularly HIF-1?, and has potency in the manufacture of a medicament for treatment and/or prophylaxis and/or adjuvant therapy of anemia, acute ischemic reperfusion injury.Type: ApplicationFiled: November 20, 2017Publication date: May 17, 2018Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song LI, Junhai XIAO, Lili WANG, Long LONG, Wei LI, Haoming LUO, Feifei LI, Wu ZHONG, Zhibing ZHENG, Yunde XIE, Xingzhou LI, Xinbo ZHOU, Xiaokui WANG, Ruiyuan CAO